CINCINNATI, Jul 06, 2005 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio
(NASDAQ:VIVO) today announced that it has been added to Mergent's
Dividend Achievers Index(TM) for 2005. This index is made up of 314
stocks composed of U.S. companies with the most consistent records of
annual dividend increases.
Quoting from Mergent's press release, "Dividend Achievers
represent the elite of the U.S. stock market. These are generally well
known companies that as a group have been shown to consistently
outperform the overall market." The press release went on to comment,
"Not only do these companies represent the very best of U.S. stocks,
but as a group they offer a relatively low-risk investment and of
course there are significant tax breaks that further increase the
potential yield to the ordinary investor."
William J. Motto, Chairman and Chief Executive Officer, stated,
"We are very pleased to have been added to the Mergent's Dividend
Achievers Index(TM) for the second year in a row. Our long-standing
cash dividend policy has served shareholders well with thirteen
increases during the past fifteen years. Our current indicated annual
cash dividend rate is $0.48 per share. With our strong cash flow from
operations, we are able to internally fund the company's growth and
concurrently payout between 75% and 85% of our net earnings in cash
dividends to shareholders."
Meridian is a fully integrated life science company that
manufactures, markets and distributes a broad range of innovative
diagnostic test kits, purified reagents and related products and
offers biopharmaceutical enabling technologies. Utilizing a variety of
methods, these products provide accuracy, simplicity and speed in the
early diagnosis and treatment of common medical conditions, such as
gastrointestinal, viral, and respiratory infections. Meridian
diagnostic products are used outside of the human body and require
little or no special equipment. The Company's products are designed to
enhance patient well-being while reducing the total outcome costs of
healthcare. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology,
parasitology and fungal disease diagnosis. In addition, Meridian is a
supplier of rare reagents and specialty biologicals along with
proteins and other biologicals used by biopharmaceutical companies
engaged in research for new drugs and vaccines. The Company markets
its products to hospitals, reference laboratories, research centers,
veterinary testing centers, physician offices and diagnostics
manufacturers in more than 60 countries around the world. The
Company's shares are traded through Nasdaq's National Market, symbol
VIVO. Meridian's website address is www.meridianbioscience.com.
SOURCE: Meridian Bioscience, Inc.
Meridian Bioscience, Inc.
John A. Kraeutler, 513-271-3700